ÂÜÀòÂÒÂ×

Melanie Leveridge is a seasoned professional in the pharmaceutical industry with significant expertise in discovery biology and assay development. Currently serving as Vice President of Discovery Biology at AstraZeneca since April 2024, Melanie leads global teams in assay and reagent generation. Melanie has been a volunteer board member at ELRIG UK since 2017, becoming Chair of the Board in 2020, where responsibilities include setting strategic direction and ensuring financial sustainability. Previously, at GSK from 2005 to April 2024, Melanie held several roles, culminating in the Head of Screening, Profiling & Mechanistic Biology, where leadership of a team focused on small molecule drug discovery and global compound management was key. Melanie began their career as a Cell Culture Scientist at Merck Sharp & Dohme. Educationally, Melanie earned a BSc in Biology from the University of Bristol between 2002 and 2005.